Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors

Oncogene

Volumn 35, Issue 21, 2016, Pages 2777-2788

  Ferrer, I ^a   Verdugo Sivianes, E M ^a   Castilla, M A ^a   Melendez, R ^a   Marin, J J ^a,b   Munoz Galvan S ^a   Lopez Guerra, J L ^c   Vieites, B ^c   Ortiz Gordillo, M J ^c   De Leon J M ^c   Praena Fernandez, J M ^c   Perez, M ^a   Palacios, J ^d   Carnero, A ^a,e  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; COMPLEMENTARY DNA; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; SHORT HAIRPIN RNA; SPINOPHILIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; ACTIN BINDING PROTEIN; NERVE PROTEIN; NEURABIN;

ARTICLE; BREAST TUMOR; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ECTOPIC EXPRESSION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; COHORT ANALYSIS; DEFICIENCY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HUMANS; MICROFILAMENT PROTEINS; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PROGNOSIS;

EID: 84971225664     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.341     Document Type: Article

References (52)

1. Allen PB. Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci USA 1997 94 9956-9961.
2. Satoh A, Nakanishi H, Obaishi H, Wada M, Takahashi K, Satoh K, et al. Neurabin-II/.spinophilin. An actin filament-binding protein with one pdz domain localized at cadherin-based cell-cell adhesion sites. J Biol Chem. 1998; 273: 3470-3475.
3. Sarrouilhe D, di Tommaso A, Metaye T, Ladeveze V. Spinophilin: from partners to functions. Biochimie. 2006; 88: 1099-1113.
4. Carnero A. Spinophilin: a new tumor suppressor at 17q21. Curr Mol Med. 2012; 12: 528-535.
5. Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, Borrelli L, et al. The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 proteinphosphatase-binding protein. J Biol Chem. 2001; 276: 14161-14169.
6. Brady AE, Wang Q, Colbran RJ, Allen PB, Greengard P, Limbird LE. Spinophilin stabilizes cell surface expression of alpha 2B-Adrenergic receptors. J Biol Chem. 2003; 278: 32405-32412.
7. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science. 2004; 304: 1940-1944.
8. Kuntziger T, Landsverk HB, Collas P, Syljuasen RG. Protein phosphatase 1 regulators in DNA damage signaling. Cell Cycle. 2011; 10: 1356-1362.
9. Allen PB, Zachariou V, Svenningsson P, Lepore AC, Centonze D, Costa C, et al. Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. Neuroscience. 2006; 140: 897-911.
10. Hsieh-Wilson LC, Allen PB, Watanabe T, Nairn AC, Greengard P. Characterization of the neuronal targeting protein spinophilin and its interactions with protein phosphatase-1. Biochemistry. 1999; 38: 4365-4373.
11. Porter DE, Steel CM, Cohen BB, Wallace MR, Carothers A, Chetty U, et al. Genetic linkage analysis applied to unaffected women from families with breast cancer can discriminate high- from low-risk individuals. Br J Surg. 1993; 80: 1381-1385.
12. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg. 1994; 81: 1512-1515.
13. Cohen BB, Porter DE, Wallace MR, Carothers A, Steel CM. Linkage of a major breast cancer gene to chromosome 17q12-21: results from 15 Edinburgh families. Am J Hum Genet. 1993; 52: 723-729.
14. Tseng SL, Yu IC, Yue CT, Chang SF, Chang TM, Wu CW, et al. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer. Genes Chromosomes Cancer. 1997; 20: 377-382.
15. Smith SA, Easton DF, Ford D, Peto J, Anderson K, Averill D, et al. Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet. 1993; 52: 767-776.
16. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993; 52: 678-701.
17. Abujiang P, Mori TJ, Takahashi T, Tanaka F, Kasyu I, Hitomi S, et al. Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers. Oncogene. 1998; 17: 3029-3033.
18. Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, et al. Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol. 2011; 225: 73-82.
19. Aigelsreiter AM, Aigelsreiter A, Wehrschuetz M, Ress AL, Koller K, Salzwimmer M, et al. Loss of the putative tumor suppressor protein spinophilin is associated with poor prognosis in head and neck cancer. Hum Pathol. 2014; 45: 683-690.
20. Aigelsreiter A, Ress AL, Bettermann K, Schauer S, Koller K, Eisner F, et al. Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma. Br J Cancer. 2013; 108: 1830-1837.
21. Estevez-Garcia P, Lopez-Calderero I, Molina-Pinelo S, Munoz-Galvan S, Salinas A, Gomez-Izquierdo L, et al. Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. Clin Cancer Res. 2013; 19: 3925-3935.
22. Ouimet CC, Katona I, Allen P, Freund TF, Greengard P. Cellular and subcellular distribution of spinophilin, a PP1 regulatory protein that bundles F-Actin in dendritic spines. J Comp Neurol. 2004; 479: 374-388.
23. Berndt N. Protein dephosphorylation and the intracellular control of the cell number. Front Biosci. 1999; 4: D22-D42.
24. Ferrer I, Blanco-Aparicio C, Peregrina S, Canamero M, Fominaya J, Cecilia Y, et al. Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle. 2011; 10: 2751-2762.
25. Ferrer I, Peregrino S, Canamero M, Cecilia Y, Blanco-Aparicio C, Carnero A. Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle. 2011; 10: 1948-1955.
26. Galderisi U, Cipollaro M, Giordano A. The retinoblastoma gene is involved in multiple aspects of stem cell biology. Oncogene. 2006; 25: 5250-5256.
27. Santamaria D, Malumbres M. Tumor suppression by Spinophilin. Cell Cycle. 2011; 10: 2831-2832.
28. Santra M, Santra S, Buller B, Santra K, Nallani A, Chopp M. Effect of doublecortin on self-renewal and differentiation in brain tumor stem cells. Cancer Sci. 2011; 102: 1350-1357.
29. Santra M, Zhang X, Santra S, Jiang F, Chopp M. Ectopic doublecortin gene expression suppresses the malignant phenotype in glioblastoma cells. Cancer Res. 2006; 66: 11726-11735.
30. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983-3988.
31. Mannello F. Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med. 2013; 11: 169.
32. Mannello F, Ligi D. Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer. 2013; 13: 344.
33. Ghebeh H, Sleiman GM, Manogaran PS, Al-Mazrou A, Barhoush E, Al-Mohanna FH, et al. Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer. 2013; 13: 289.
34. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003; 36: 59-72.
35. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17: 1253-1270.
36. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65: 5506-5511.
37. Locke M, Heywood M, Fawell S, Mackenzie IC. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res. 2005; 65: 8944-8950.
38. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004; 101: 14228-14233.
39. Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in many cancer cell lines. Cell Cycle. 2004; 3: 414-415.
40. Resnicoff M, Medrano EE, Podhajcer OL, Bravo AI, Bover L, Mordoh J. Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: a model to analyze the heterogeneity of human breast cancer. Proc Natl Acad Sci USA. 1987; 84: 7295-7299.
41. Barrandon Y, Green H. Three clonal types of keratinocyte with different capacities for multiplication. Proc Natl Acad Sci USA. 1987; 84: 2302-2306.
42. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014; 511: 246-250.
43. Siegle JM, Basin A, Sastre-Perona A, Yonekubo Y, Brown J, Sennett R, et al. SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma. Nat Commun. 2014; 5: 4511.
44. Castro ME, Ferrer I, Cascon A, Guijarro MV, Lleonart M, Cajal SR, et al. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis. 2008; 29: 491-499.
45. Ress AL, Stiegelbauer V, Schwarzenbacher D, Deutsch A, Perakis S, Ling H, et al. Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. Oncotarget. 2014; 5: 8492-8502.
46. Pinto CA, Widodo E, Waltham M, Thompson EW. Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance. Cancer Lett. 2013; 341: 56-62.
47. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11: 259-273.
48. Chang CC. Recent translational research: stem cells as the roots of breast cancer. Breast Cancer Res. 2006; 8: 103.
49. Tsukada M, Prokscha A, Oldekamp J, Eichele G. Identification of neurabin II as a novel doublecortin interacting protein. Mech Dev. 2003; 120: 1033-1043.
50. Bielas SL, Serneo FF, Chechlacz M, Deerinck TJ, Perkins GA, Allen PB, et al. Spinophilin facilitates dephosphorylation of doublecortin by PP1 to mediate microtubule bundling at the axonal wrist. Cell. 2007; 129: 579-591.
51. Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat. 2001; 66: 135-142.
52. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, et al. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 2007; 28: 1646-1652.